Abstract
Pancreatic adenocarcinoma (PDAC) has been historically unresponsive to immunotherapy, predominantly due to lower antigen loads and a lack of tumor-infiltrating dendritic cells (DCs) and T cells. A recent study by Mahadevan and colleagues demonstrates that increasing DC infiltration through use of an engineered DC1 vaccine can sensitize PDAC to immunotherapy.
Original language | English |
---|---|
Pages (from-to) | 1095-1096 |
Number of pages | 2 |
Journal | Trends in Pharmacological Sciences |
Volume | 45 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2024 |
Keywords
- adaptive immunity
- checkpoint blockade
- dendritic cell
- pancreatic cancer
- pancreatitis